June 20, 2016
ProAxsis (www.proaxsis.com) is undertaking business development activities with Invest Northern Ireland support. Speaking about the plans, Dr David Ribeiro, CEO of ProAxsis, said: “This funding will allow us to complete further commercial activities concerning the development of our point-of-care test, for detecting neutrophil elastase as a biomarker of infection and inflammation in patients with chronic respiratory diseases such as COPD and cystic fibrosis. Invest NI is a fantastic supporter of innovative companies based in Northern Ireland, and we’re very grateful for their continuing support.”
Invest NI has offered ProAxsis £48,000 to support its market development activities.
Ian Murphy, Invest NI’s Director of Growth and Scaling, added: “ProAxsis is a highly innovative University spinout focused on growing its customer base outside Northern Ireland. Invest NI’s support is helping the business gain greater insight into the potential business opportunities for its medical technology so that it can reach its export potential.”
Any queries concerning ProAxsis’ Immunoassays for measuring active neutrophil elastase and active Cathepsin G, or any other aspects of the company’s proprietary ProteaseTag® technology, can be directed to email@example.com. For further information about Invest Northern Ireland, please visit www.investni.com
ProAxsis is part of the NetScientific group and is one of the group’s core portfolio companies. The company is also supported by QUBIS, the commercialisation arm of Queens University.
June 20, 2016